A B S T R A C T Studies of immunoglobulin synthesis, total body tumor cell number, and tumor kinetics were carried out in a series of patients with IgG multiple myeloma. The changes in tumor size associated with tumor growth or with regression were underestimated when the concentration of serum M-component was used as the sole index of tumor mass. Calculation of the total body M-component synthetic rate (corrected for concentration-dependent changes in IgG metabolism) and tumor cell number gave a more accurate and predictable estimate of changes in tumor size. Tumor growth and drug-induced tumor regression were found to follow Gompertzian kinetics, with progressive retardation of the rate of change of tumor size in both of these circumstances. This retardation effect, describable with a constant a, may be caused by a shift in the proportion of tumor cells in the proliferative cycle. Drug sensitivity of the tumor could be described quantitatively with a calculation of Bo, the tumor's initial sensitivity to a given drug regimen. Of particular clinical significance, the magnitude of a given patient's tumor regression could be predicted from the ratio of This work was presented in part at
INTRODUCTION
Kinetic analysis of growth of disseminated malignancies in man is a subject of major importance, both for understanding the pathophysiology of cancer and for planning optimal therapy. Convincing evidence of the therapeutic ramifications of such kinetic analysis is found in the series of dramatic demonstrations with various animal tumors; knowledge of the cell population and cell-cycle kinetics of certain tumors has provided the necessary foundation for designing curative chemotherapy (1) (2) (3) (4) . Animal tumors, which arise from-and can be transplanted with-a single neoplastic cell, can be assessed serially, using measurements of tumor mass; by further transplantation studies, the population and cellular kinetics of viable tumor stem cells can be studied during growth and during drug-induced regression of the neoplasm (5) .
Although measurements of tumor size can sometimes be obtained in man, transplantation studies cannot be done, and other methods of serially estimating the number of viable tumor cells must be found. Multiple
The Journal of Clinical Investigation Volume 51 July 1972 myeloma may represent an "ideal" disseminated neoplasm for kinetic study, as the population of tumor cells can be readily sampled, the cells almost always produce a marker immunoglobulin (M-component)l whose metabolism has been well characterized, and the tumor appears to arise from a single neoplastic cell clone. Previous studies from this laboratory (6, 7) established that measurements of synthesis of M-component in vivo and in vitro could be used to determine the total number of tumor cells present in patients with multiple myeloma. In those patients, clinical manifestations of disease did not become apparent until more than 1011 myeloma cells were present in the body. Our present investigations were designed to provide a firm mathematical basis for the application of predictive kinetic analysis to the design and evaluation of treatment of multiple myeloma, and to provide new insights into its natural history.
METHODS
Patient studies. Patients with well-documented IgG multiple myeloma (subclasses IgG1 and IgG2) were selected for study. Clinical and immunologic criteria used for diagnosis and staging of these patients were detailed previously, as were data on metabolism in vivo of [1251-labeled] IgG and on total body tumor cell number in 10 of these patients (6) .
Bone marrow aspirates were collected in heparin; shortterm tissue cultures were prepared for studies of cellular synthesis of myeloma protein (IgGmp) (8) . Newly synthesized IgG was measured with the "sandwich" radioimmunoassay technique (9) . Cellulose acetate electrophoresis and densitometry2 were performed at least monthly. The serum concentration of IgGmp was determined by careful analysis of the electrophoretic patterns. Plasma volume was measured by the Nuclear Medicine division of this institution every 3 months with the [E251-labeled] albumin technique. The total body synthetic rate of IgGmp was calculated from the concentration of IgGmp in serum, the plasma volume, and the body weight as described below.
In addition to the cases studied at this institution, records on 19 patients treated in cooperating institutions of the Southwest Cancer Chemotherapy Study Group (SWCCSG) were also analyzed. Plasma volumes for these patients were estimated on the basis of height and weight, using the technique of Fairbanks and Tauxe (10) From our studies in man, we have estimated 0.16 as the value for a and, as did Waldmann and Strober (11), we used 147 mg of IgG/kg per day as the value for D. In the steady state, the total IgG catabolized by the body (f. Vc) equals the total IgG synthesized by the body. It should be noted that f is governed by the total serum IgG concentration, not just the concentration of the M-component. As a result of the severe deficiency in normal immunoglobulins which occurs in myeloma, the concentration of M-component alone is usually satisfactory; in the presence of a significant amount of normal IgG in addition to the IgGmp, total IgG must be measured, and the calculated f must be used to determine the turnover rate of the M-component.
As described previously (6) Fig. 1 .
THEORETICAL BACKGROUND
The curves (in Fig. 1 ) demonstrate that neither tumor growth nor response to treatment was exponential, but rather that the rate of these processes appears to be continuously changing. As extensively formulated first by Laird, embryonic tissues (12) and a variety of animal tumors (13, 14) have a similar growth pattern which can be described by a Gompertzian function. Subsequent work at the Southern Research Institute has extended this concept (4, 15, 16) .
Growth, which occurs in Gompertzian fashion, could be due to any of the following situations: (a) a decreasing proliferative fraction with an increasing number of resting cells (Go), an increasing number of nonclonogenic cells, or both; (b) an increase in the mean cell-cycle time; or (c) a continuous increase in the fractional cell loss. Griswold, Simpson-Herren, and Schabel (17), working with the metastatic plasmacytoma of the hamster (PLA-1), have shown that the slowing of tumor growth is due primarily to an increasingly large fraction of the cells in a nonproliferative state, with a possible increase in the fraction of cells lost. Measurements of the cell-cycle time for the hamster plasmacytoma by Griswold et al. (17) A pplication of the Gompertz equation to tumor regression data and derivation of a for tumor growth. As developed by Dr. Hugo M. Martinez of this institution and detailed in Appendix II, mathematical derivation shows that the retardation constant a applies to both tumor regression and tumor growth. Thus, in circumstances where a consistent treatment program was used for a given myeloma patient, it was possible to derive the retardation constant necessary to describe the dynamics of the disease. With certain assumptions, stated below, the derived a could also be used for reconstruction of the subclinical growth phase of the tumor clone from its initial doubling.
Estimation of the initial growth rate (A,). Values for A,, the instantaneous growth rate at the time of the tumor's initial doubling (start of growth), cannot be derived from tumor regression data. Its approximation can be made only by analysis of progressive tumor growth in untreated cases, or by addition of several constraints to the Gompertz function which are based on generally accepted survival data. The constraints added for this purpose were an average survival time from diagnosis in untreated or drug-resistant cases of less than 24 months (median 18 months) (21) , a threshold tumor cell number at diagnosis of at least 2.5 X 1011 myeloma cells in the body (6) and an average tumor doubling time of 4-6 months during the clinical phase of disease (6, 22, 23) . These three constraints, plus a value for a, provide all the data necessary for a solution of the Gompertz equation. RESULTS Cellular immunoglobulin synthetic rates. Measurements of the cellular IgG synthetic rate in vitro were made in a total of 36 patients with IgG multiple myeloma. 22 of these patients have been studied serially during their clinical course, and a total of 67 studies (range, 2-8 per patient) have been performed. Synthetic rates were determined at the time of presentation and during subsequent tumor regression or remission. Bone marrow specimens for culture were obtained when the patients were receiving no therapy (e.g., before treatment was begun; off treatment; or immediately before the beginning of an intermittent course of melphalan, prednisone, or both) or while they were receiving treatment with low daily doses of melphalan. Synthetic rates among these patients ranged from 1.5 to 34 pg/myeloma cell per day (mean, 14.5+9.6). The cellular IgG synthetic rates have remained constant 4-10% for as long as 3 yr for all patients studied serially under these circumstances, whether or not the patient was receiving therapy and independent of the number of tumor cells in the body. Additional studies were performed during 4 day, highdose, "pulse" chemotherapy; however, these data are not included as they gave disparate results, probably because of the acute effects of intensive therapy. None of the in vitro studies reported here was carried out during relapse on continued chemotherapy.
Comparison of predicted and measured IgG metabolic parameters. Data on 10 patients on whom metabolic turnover studies had been done were processed with the computer program to calculate the fractional catabolic rate (f) by means of the metabolic equation. Table I summarizes this comparison; the metabolic equation provides an excellent approximation of the f measured for IgG by metabolic turnover study. The average deviation from the predicted value was 8% (+3.9% SEM). Predicted plasma volumes for these 10 patients (based on height, weight, and hematocrit) also agreed well with the measured plasma volumes. One patient (E. M.) had an initial plasma volume more than 25% greater than predicted. However, it is important to note that the expanded plasma volume in this patient contracted during chemotherapy even though there was no significant change in hematocrit.
Relationship of concentration-dependent changes in IgG metabolism to tumor regression. Data were analyzed on 15 SWCCSG patients with IgG myeloma, who were (Table II) , and regression and growth kinetics (Table III) ., albumin. In four patients, data were supplied by the SWCCSG and fixed cellular IgG synthetic rates and plasma volumes were estimated with the techniques described above. Kinetics of tumor regression. A characteristic mode of tumor regression is observed when myeloma patients are treated with alkylating agents alone or combined with prednisone. The tumor regresses rapidly at first, then slows and reaches a plateau size which is stable for a period of months or years. The rapidity with which myeloma cell number initially decreased with treatment was dependent upon Bo, the sensitivity of the tumor to drug. With a large B0, the initial rate of tumor regression was rapid. This effect occurred in three patients (J. H., W. W., T. D.); each had a B0 of -0.039 or greater. In these patients, the tumor cell number halved in less than 30 days.
The retardation constants a for these 11 patients were all between 0.004 and 0.022, suggesting a narrow range for this constant for myeloma cells. The total degree of tumor regression is not dependent solely upon either B. or a but, rather, upon their ratio. Optimal tumor response thus occurs when B, is large and a is small; that is, when the ratio of these two is large. It follows from the Gompertz equation that a ratio of B0:a of greater than 2.4 predicts a tumor regression of greater than 1 log. Regressions which approximated this magnitude were induced in 5 of the 11 patients studied (87.9-98.2% regression). Three of the five patients who had significant tumor regressions (N. S., S. A., K. L.) had tumors less sensitive to drug than the three patients discussed above (B,, values of -0.009 to -0.028), but their values for a were also extremely small. The predictive capability of kinetic analysis is illustrated in Fig. 3 , wherein final measured and predicted tumor cell numbers are shown for patient W. W. In this instance, the plateau of tumor during treatment was predicted many months in advance. DISCUSSION Unlike the techniques of measurement of tumor volume which have been widely applied in previous studies of animal and human tumors, derivation of serial tumor mass from measurements of immunoglobulin synthesis is not subject to the difficulties of measuring tumor nodules which may contain variable but significant numbers of nonviable cells, normal tissue elements, and interstitial fluid. Our studies do entail a concept of cell death which is somewhat different from that generally used by the radiobiologist, who defines death as the loss of a cell's capability to serve as a stem cell (i.e., it becomes sterile, or nonclonogenic) (24) . In our kinetic studies, myeloma cells that we call dead on the basis of their loss of capability to synthesize an M-component are most likely "dead and gone," rather than simply nonclonogenic. Substantiation of this impression was recently provided when we analyzed electrophoretic data obtained by Bergsagel on a patient whom he treated with total body irradiation (25) . In this patient, the half-life of irradiated myeloma cells was at least 2 wk, during which time they continued to secrete the M-component.
Recognition that changes in IgG metabolism, which occur as a concentration-dependent phenomenon, could lead to significant underestimation of the degree of change in total body M-component synthesis (and tumor mass) prompted us to develop a technique to correct for these metabolic effects. IgG clones account for slightly more than half of all cases of myeloma (26) (27) (28) ; errors in interpretation of response in IgG myeloma could significantly alter response data for myeloma in general. Analysis of so-called "nonresponders" in the SWCCSG experience indicated that some of these patients had actually had a significant (50%) reduction in the amount of tumor (Fig.  4) . Deductive analysis, which proved that an a determined during tumor regression also applied to the earlier period of tumor growth, confirmed the validity of use of regression data to determine growth characteristics (see Appendix II).
This approach broadens the applicability of growth analysis in human tumors and provides a more representative sample of patients than could ethically be obtained in untreated patients. Study of an untreated patient group would be prejudiced toward the selection of patients with slowly growing tumors because beneficial therapy cannot be justifiably withheld from patients with progressive myeloma (e.g., 29). Additionally, analysis of the process of tumor relapse during continued therapy may not yield information which is representative of the growth of the untreated or drugresponsive neoplasm; "subcloning phenomena," as described by Coffino, Laskov, and Scharff for mouse myeloma (30) and by Hobbs for myeloma in man (31) , do appear to occur (we have observed this feature in several of our patients). The measurements of immunoglobulin synthesis in vitro reported here were obtained by sampling 107-108 bone marrow cells at the time of initial presentation and during regression and plateau phases of myeloma; we have not observed significant changes in the rate or type of cellular M-component synthesis. We recognize that subcloning does occur during relapse in at least 5% of cases, and serial measurements of M-component synthesis in vitro will be needed to characterize cellular function in the resistant phase of the disease. We are investigating this phenomenon but have, as yet, relatively few measurements. However, analysis of some electrophoretic data from patients in relapse suggests that a drug-resistant clone appearing during relapse may have a much smaller value for a.
Our interpretation of the cellular and population events which account for these growth and regression phenomena must be considered tentative; however, the demonstration that the identical a applies to both circumstances strongly supports the concept that reciprocal changes are occurring in the size of the proliferating or growth fraction of the tumor. During the period of progressive growth of the tumor the proliferating fraction appears to decrease, while during the period of regression during treatment a larger fraction of the remaining tumor mass appears to shift into the proliferative compartment. This form of retarded regression could be anticipated whenever a treatment (e.g., an alkylating agent) produces a constant fractional kill of tumor cells. Such therapy could be considered as an additional environmental force favoring cell death; it would force the tumor to seek a new (and lower) population size, with the resulting regression and plateau in size representing a newly established balance between increased cell death due to treatment and increased tumor cell birth rate resulting from an expanded proliferative fraction. The plateau phenomenon during remission probably does not reflect the acquisition of drug resistance; a prolonged plateau phase (several years in some of our patients) could not be anticipated in a drug-resistant tumor-the tumor mass would increase progressively even with continued therapy.
The capability to predict the maximum degree of regression and time until plateau of tumor size for any form of therapy should be clinically important. If the plateauing phenomenon during therapy is caused by an expansion of the proliferative fraction of the tumor as the total population is reduced, or if the residual cells are mostly nonclonogenic, use of antimetabolites that attack the tumor stem cells during the proliferative cycle would be most rational after the tumor had first been reduced significantly in size by a noncycle-specific agent such as an alkylating agent. The plasmacytoma of the hamster, which also grows in Gompertzian fashion, appears to display precisely this phenomenon (17) . It cannot be cured with a potent cycle-active agent (cytosine arabinoside) when the tumor is extensive, but it can be cured with the same drug if the total mass is first reduced by several logs with alkylating agents (reversal of this sequence is ineffective).
Our estimated generation times for myeloma cells are similar to those measured in man by Killmann et al. (18) . Their tritiated thymidine-labeling studies in vivo showed that the proliferative fraction is very small at the clinical stage of disease. Analysis of our kinetic data on the theoretical proliferative fraction (Theoretical Background) suggests that, in most patients, approximately 6.5% of myeloma cells are in the proliferative fraction at the clinical threshold of 2.5 X 1011 tumor cells. Flash-labeling studies with tritiated thymidine in vitro suggest that the labeling index is extremely low (less than 3.5%) when measured at high total body densities of tumor cell number (7) , although it remains to be established whether the labeling index increases significantly during remission. Study of the labeling index at low tumor cell density presents substantial problems due to the difficulties inherent in identifying as myeloma cells a small percentage of all marrow cells and in identifying an even smaller fraction of these as being labeled. However, the possibility of an expanded proliferative fraction during regression can be tested with the use of clinical trials of cycle-active agents in patients who have had very large tumor regressions. For evaluation of such a trial, an extremely sensitive indicator of the myeloma protein would be required once the M-component was no longer detectable by electrophoresis.
Reconstructing the natural history of myeloma, it appears that its duration is shorter than had previously been considered (6, 22) . Our calculations on the subclinical phase of disease (up to 2.5 X 1011 cells) suggest that this initial period of tumor growth occurs in from less than 4 Should a feedback inhibitor produced by myeloma cells also affect normal antibody-producing clones, then one major clinical feature of myeloma may be clarified. An antibody-deficiency syndrome is a constant feature of this disorder; it appears to be due to a reduction in the number of normal-immunoglobulin-producing clones rather than a change in immunoglobulin catabolism (33) (34) (35) . Extrapolating from our measurements in myeloma, we calculate that the mass of all antibodyproducing clones in normal man is some 3 X 1011 cells (about 300 g). Based on our measurements, patients with myeloma have at least a 1 log reduction in the number of normal antibody-producing clones in the body. In the mouse, recent studies by Zolla (36) present strong evidence that myeloma cells do have depressive effects on normal immune cell proliferation. Her studies demonstrate that subcutaneously transplanted myelomas suppress the proliferation of antibody-producing cells progressively as they grow.
Investigations of the growth of myeloma may thus not only clarify the natural history of the disorder and provide an approach to predictive cancer chemotherapy, but may also provide some insight into the processes that regulate neoplastic and normal cell growth. Assumptions. (a) The tumor's growth can be described with Gompertzian kinetics, i.e., at any time I, the growth of the tumor may be described as: N(t) = N(0)e (b) The tumor is treated with a fixed dose and schedule of a cycle-nonspecific drug (e.g., an alkylating agent such as melphalan) that causes a fixed percentage kill independent of the total number of cells or their position in the cell cycle. 
